EHA 2022 | Factors to consider when selecting myeloma patients for antibody therapy
Rakesh Popat
• 10 Jun 2022
In this video, Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses patient selection for antibody therapy in relapsed/refractory multiple myeloma (R/R MM). Dr Popat explains that several factors must be considered when choosing between bispecific antibodies or antibody-drug conjugates (ADCs), such as the side effect profile of each agent, patient frailty, and the aggressiveness of disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
